Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cellebrite DI Sees Q3 Sales $121.000M-$126.000M vs $124.357M Est

Author: Benzinga Newsdesk | August 14, 2025 06:03am
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.

Posted In: CLBT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist